Literature DB >> 33599811

Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease.

Yun Zhou1, Shaney Flores2, Syahir Mansor2, Russ C Hornbeck2, Zhude Tu2, Joel S Perlmutter2,3, Beau Ances4, John C Morris3,4, Robert J Gropler2, Tammie L S Benzinger2,3,4.   

Abstract

PURPOSE: Recent studies have shown that standard compartmental models using plasma input or the cerebellum reference tissue input are generally not reliable for quantifying tau burden in dynamic 18F-flortaucipir PET studies of Alzheimer disease. So far, the optimal reference region for estimating 18F-flortaucipir delivery and specific tau binding has yet to be determined. The objective of the study is to improve 18F-flortaucipir brain tau PET quantification using a spatially constrained kinetic model with dual reference tissues.
METHODS: Participants were classified as either cognitively normal (CN) or cognitively impaired (CI) based on clinical assessment. T1-weighted structural MRI and 105-min dynamic 18F-flortaucipir PET scans were acquired for each participant. Using both a simplified reference tissue model (SRTM2) and Logan plot with either cerebellum gray matter or centrum semiovale (CS) white matter as the reference tissue, we estimated distribution volume ratios (DVRs) and the relative transport rate constant R1 for region of interest-based (ROI) and voxelwise-based analyses. Conventional linear regression (LR) and LR with spatially constrained (LRSC) parametric imaging algorithms were then evaluated. Noise-induced bias in the parametric images was compared to estimates from ROI time activity curve-based kinetic modeling. We finally evaluated standardized uptake value ratios at early phase (SUVREP, 0.7-2.9 min) and late phase (SUVRLP, 80-105 min) to approximate R1 and DVR, respectively.
RESULTS: The percent coefficients of variation of R1 and DVR estimates from SRTM2 with spatially constrained modeling were comparable to those from the Logan plot and SUVRs. The SRTM2 using CS reference tissue with LRSC reduced noise-induced underestimation in the LR generated DVR images to negligible levels (< 1%). Inconsistent overestimation of DVR in the SUVRLP only occurred using the cerebellum reference tissue-based measurements. The CS reference tissue-based DVR and SUVRLP, and cerebellum-based SUVREP and R1 provided higher Cohen's effect size d to detect increased tau deposition and reduced relative tracer transport rate in CI individuals.
CONCLUSION: Using a spatially constrained kinetic model with dual reference tissues significantly improved quantification of relative perfusion and tau binding. Cerebellum and CS are the suggested reference tissues to estimate R1 and DVR, respectively, for dynamic 18F-flortaucipir PET studies. Cerebellum-based SUVREP and CS-based SUVRLP may be used to simplify 18F-flortaucipir PET study.

Entities:  

Keywords:  18F-Flortaucipir PET; Alzheimer disease; Dual reference tissues; Logan plot; SRTM; SUVR; Spatially constrained kinetic modeling

Year:  2021        PMID: 33599811     DOI: 10.1007/s00259-020-05134-w

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  58 in total

Review 1.  A review on Alzheimer's disease pathophysiology and its management: an update.

Authors:  Anil Kumar; Arti Singh
Journal:  Pharmacol Rep       Date:  2014-09-22       Impact factor: 3.024

Review 2.  Update on Alzheimer's Disease Therapy and Prevention Strategies.

Authors:  W Vallen Graham; Alessandra Bonito-Oliva; Thomas P Sakmar
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

3.  Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

Authors:  Suzanne L Baker; Samuel N Lockhart; Julie C Price; Mark He; Ronald H Huesman; Daniel Schonhaut; Jamie Faria; Gil Rabinovici; William J Jagust
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

4.  Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.

Authors:  Olivier Barret; David Alagille; Sandra Sanabria; Robert A Comley; Robby M Weimer; Edilio Borroni; Mark Mintun; Nicholas Seneca; Caroline Papin; Thomas Morley; Ken Marek; John P Seibyl; Gilles D Tamagnan; Danna Jennings
Journal:  J Nucl Med       Date:  2016-12-01       Impact factor: 10.057

5.  Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology.

Authors:  Andreas Hahn; Martin Schain; Maria Erlandsson; Petter Sjölin; Gregory M James; Olof T Strandberg; Douglas Hägerström; Rupert Lanzenberger; Jonas Jögi; Tomas G Olsson; Ruben Smith; Oskar Hansson
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

Review 6.  Alzheimer disease therapy--moving from amyloid-β to tau.

Authors:  Ezio Giacobini; Gabriel Gold
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 7.  Neurofibrillary tangles and Alzheimer's disease.

Authors:  J P Brion
Journal:  Eur Neurol       Date:  1998-10       Impact factor: 1.710

8.  Quantification of Tau Load Using [18F]AV1451 PET.

Authors:  Sandeep S V Golla; Tessa Timmers; Rik Ossenkoppele; Colin Groot; Sander Verfaillie; Philip Scheltens; Wiesje M van der Flier; Lothar Schwarte; Mark A Mintun; Michael Devous; Robert C Schuit; Albert D Windhorst; Adriaan A Lammertsma; Ronald Boellaard; Bart N M van Berckel; Maqsood Yaqub
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 9.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

10.  Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.

Authors:  Sepideh Shokouhi; John W Mckay; Suzanne L Baker; Hakmook Kang; Aaron B Brill; Harry E Gwirtsman; William R Riddle; Daniel O Claassen; Baxter P Rogers
Journal:  Alzheimers Res Ther       Date:  2016-01-15       Impact factor: 6.982

View more
  2 in total

1.  Tracer-specific reference tissues selection improves detection of 18 F-FDG, 18 F-florbetapir, and 18 F-flortaucipir PET SUVR changes in Alzheimer's disease.

Authors:  Yanxiao Li; Yee Ling Ng; Manish D Paranjpe; Qi Ge; Fengyun Gu; Panlong Li; Shaozhen Yan; Jie Lu; Xiuying Wang; Yun Zhou
Journal:  Hum Brain Mapp       Date:  2022-02-15       Impact factor: 5.038

2.  Motion correction and its impact on quantification in dynamic total-body 18F-fluorodeoxyglucose PET.

Authors:  Tao Sun; Yaping Wu; Wei Wei; Fangfang Fu; Nan Meng; Hongzhao Chen; Xiaochen Li; Yan Bai; Zhenguo Wang; Jie Ding; Debin Hu; Chaojie Chen; Zhanli Hu; Dong Liang; Xin Liu; Hairong Zheng; Yongfeng Yang; Yun Zhou; Meiyun Wang
Journal:  EJNMMI Phys       Date:  2022-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.